# Dompé Farmaceutici S.p.A clinical trials: 52 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 52 trials with Dompé Farmaceutici S.p.A as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Dompé Farmaceutici S.p.A: 52 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/domp-farmaceutici-s-p-a

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 52
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 52, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 9, 2026 | NCT07519902 | An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED | Dompé Farmaceutici S.p.A | Phase 3 | Recruiting | Persistent Corneal Epithelial Defect | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519902) |
| March 31, 2026 | NCT07503886 | An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease | Dompé Farmaceutici S.p.A | Phase 2 | Recruiting | Dry Eye Disease (DED) | 417 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503886) |
| March 6, 2026 | NCT07453888 | Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) | Dompé Farmaceutici S.p.A | Phase 3 | Recruiting | Non-Arteritic Anterior Ischemic Optic Neuropathy | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07453888) |
| February 9, 2026 | NCT07395232 | An Efficacy and Safety Study of DFL24498 in the Treatment of AKC | Dompé Farmaceutici S.p.A | Phase 3 | Recruiting | Atopic Keratoconjunctivitis | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07395232) |
| May 13, 2024 | NCT06411145 | Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis | Dompé Farmaceutici S.p.A | Phase 4 | Withdrawn | Neurotrophic Keratitis, Neurotrophic Keratopathy, Corneal Ulcer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06411145) |
| May 13, 2024 | NCT06411132 | Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye | Dompé Farmaceutici S.p.A | Observational | Terminated | Sjögren Syndrome, Dry Eye | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06411132) |
| February 6, 2024 | NCT06244316 | A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle... | Dompé Farmaceutici S.p.A | Phase 2 | Completed | Dry Eye Disease | 317 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06244316) |
| September 23, 2022 | NCT05552261 | DEFENDO Long Term Follow-up Study in Stage 1 NK Patients | Dompé Farmaceutici S.p.A | Observational | Completed | Neurotrophic Keratitis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05552261) |
| August 11, 2022 | NCT05496868 | Add-on Reparixin in Adult Patients With ARDS | Dompé Farmaceutici S.p.A | Phase 2 | Completed | Acute Respiratory Distress Syndrome, Adult | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05496868) |
| May 10, 2022 | NCT05368402 | Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes. | Dompé Farmaceutici S.p.A | Phase 2 | Terminated | Type 1 Diabetes | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05368402) |
| February 24, 2022 | NCT05254990 | Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia | Dompé Farmaceutici S.p.A | Phase 3 | Terminated | Infectious Pneumonia, Severe COVID-19 | 414 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05254990) |
| January 28, 2022 | NCT05212701 | To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer | Dompé Farmaceutici S.p.A | Phase 2 | Withdrawn | Fatigue, Locally Advanced or Metastatic Breast Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05212701) |
| December 29, 2021 | NCT05172050 | Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients. | Dompé Farmaceutici S.p.A | Phase 2/3 | Completed | SARS CoV 2 Infection | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05172050) |
| November 29, 2021 | NCT05136170 | Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease | Dompé Farmaceutici S.p.A | Phase 3 | Completed | Dry Eye Disease | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05136170) |
| November 24, 2021 | NCT05133180 | Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study) | Dompé Farmaceutici S.p.A | Phase 3 | Completed | Dry Eye | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05133180) |
| September 5, 2021 | NCT05035368 | Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes | Dompé Farmaceutici S.p.A | Phase 2 | Withdrawn | Type I Diabetes | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05035368) |
| May 24, 2021 | NCT04899271 | A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline. | Dompé Farmaceutici S.p.A | Phase 2 | Terminated | New-onset Type 1 Diabetes | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04899271) |
| May 7, 2021 | NCT04878055 | Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia. | Dompé Farmaceutici S.p.A | Phase 3 | Completed | Pneumonia, Viral | 287 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04878055) |
| April 22, 2021 | NCT04854642 | A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers | Dompé Farmaceutici S.p.A | Phase 1 | Completed | no Condition | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04854642) |
| March 17, 2021 | NCT04803396 | Ascending Dose Tolerability Trial and PK Assessment in Healthy Volunteers After Single & Multiple Oral Intake of DF2755A | Dompé Farmaceutici S.p.A | Phase 1 | Terminated | no Condition | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04803396) |
| March 17, 2021 | NCT04802967 | A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males | Dompé Farmaceutici S.p.A | Phase 1 | Completed | No Condition | 141 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04802967) |
| March 12, 2021 | NCT04794803 | Reparixin in COVID-19 Pneumonia - Efficacy and Safety | Dompé Farmaceutici S.p.A | Phase 2/3 | Terminated | Severe Pneumonia | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04794803) |
| November 13, 2020 | NCT04628481 | A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function | Dompé Farmaceutici S.p.A | Phase 2 | Terminated | Recent Onset type1 Diabetes | 289 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04628481) |
| July 24, 2020 | NCT04485546 | Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis | Dompé Farmaceutici S.p.A | Phase 4 | Completed | Neurotrophic Keratitis | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04485546) |
| June 11, 2019 | NCT03982368 | A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye | Dompé Farmaceutici S.p.A | Phase 2 | Completed | Dry Eye Syndrome | 261 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03982368) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 9 |
| Phase 1/2 | 2 |
| Phase 2 | 21 |
| Phase 2/3 | 3 |
| Phase 3 | 10 |
| Phase 4 | 2 |
| Not applicable | 3 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 35 |
| Terminated | 10 |
| Recruiting | 4 |
| Withdrawn | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dry Eye Syndromes | 10 |
| Diabetes Mellitus, Type 1 | 6 |
| COVID-19 | 4 |
| Breast Neoplasms | 4 |
| Reperfusion Injury | 3 |
| Pneumonia | 3 |
| Toothache | 2 |
| Neuralgia | 2 |
| Xerophthalmia | 2 |
| Keratitis | 2 |
| Corneal Ulcer | 2 |
| Kidney Diseases | 1 |
| Cough | 1 |
| Sjogren's Syndrome | 1 |
| Pneumonia, Viral | 1 |
| Pemphigoid, Bullous | 1 |
| Conjunctivitis, Allergic | 1 |
| Jacobs syndrome | 1 |
| Respiratory Distress Syndrome | 1 |
| Retinitis Pigmentosa | 1 |
| Cone-Rod Dystrophies | 1 |
| Glaucoma | 1 |
| Somatoform Disorders | 1 |
| Headache | 1 |
| Dysmenorrhea | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Caribbean restaurants in the United States](https://specstream.ai/data/businesses/caribbean-restaurants/united-states)
- [Indian restaurants in the United States](https://specstream.ai/data/businesses/indian-restaurants/united-states)
- [Salvadoran restaurants in the United States](https://specstream.ai/data/businesses/salvadoran-restaurants/united-states)
- [Bar and grill restaurants in the United States](https://specstream.ai/data/businesses/bar-and-grill-restaurants/united-states)
- [Glass companies in the United States](https://specstream.ai/data/businesses/glass-companies/united-states)
- [Primary care clinics in the United States](https://specstream.ai/data/businesses/primary-care-clinics/united-states)
